NR 565 Advanced Pharmacology Midterm Exam Prep
Document | 2026/2027 Edition | 200 Verified Questions
NR 565 Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice test is meticulously designed for nursing students preparing for the NR
565 Advanced Pharmacology midterm. It features 200 verified questions with detailed rationales,
covering essential pharmacological principles, drug classifications, and clinical applications. The
content is aligned with the latest 2026-2027 academic guidelines, ensuring relevance and accuracy.
Each question is crafted to mirror the exam format, providing a realistic simulation to enhance
readiness and confidence.
Key Features:
Pharmacokinetics and pharmacodynamics
Autonomic nervous system drugs
Cardiovascular pharmacology
Antimicrobial therapy
Endocrine and metabolic agents
Pain management and CNS drugs
Updates for 2026:
- Integrated 2026-2027 evidence-based prescribing guidelines
- Revised rationales to reflect current clinical protocols
- Added new questions on emerging drug therapies
- Updated drug interactions and safety alerts
- Enhanced distractors to better assess critical thinking
Abstract:
This practice test is an indispensable resource for advanced pharmacology students, offering a rigorous
assessment of knowledge required for the NR 565 midterm. The 200 questions are distributed across core content
areas, each with detailed rationales that explain correct answers and common misconceptions. The test emphasizes
clinical decision-making, drug safety, and patient-centered care, aligning with the competencies expected of
advanced practice nurses. By engaging with this material, students will solidify their understanding of
pharmacological mechanisms, therapeutic applications, and adverse effects. The rationales are designed to
reinforce learning and promote retention, making this an effective study tool. Updated to reflect the latest
guidelines, this practice test ensures that students are well-prepared for the challenges of the exam and future
clinical practice.
Keywords:
Advanced Pharmacology, NR 565, Midterm Exam, Practice Test, Pharmacokinetics, Drug Interactions, Clinical
Guidelines, Nursing Education
Answer Format:
Each question is followed by four answer choices, with the correct answer clearly indicated. A detailed rationale
explains why the correct answer is right and why the distractors are incorrect, referencing pharmacological
principles and clinical guidelines. This format facilitates deep understanding and application of knowledge.
Compliance Checklist:
Aligned with 2026-2027 AACN and ANA guidelines
Reflects current FDA-approved drug indications
Page 1
, Includes safety alerts and black box warnings
Covers all major drug classes in the NR 565 syllabus
Rationales cite evidence-based sources
Suitable for self-assessment and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-20 Absorption, Distribution, Metabolism, 10%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 21-40 Cholinergic, Anticholinergic, Adrenergic, 10%
Drugs Antiadrenergic Agents
Cardiovascular Pharmacology 41-70 Antihypertensives, Antiarrhythmics, 15%
Antianginals, Heart Failure Drugs
Antimicrobial Therapy 71-100 Antibiotics, Antivirals, Antifungals, 15%
Antiparasitics
Endocrine and Metabolic Agents 101-130 Insulin, Oral Hypoglycemics, Thyroid 15%
Drugs, Corticosteroids
Pain Management and CNS 131-160 Opioids, NSAIDs, Antidepressants, 15%
Drugs Anticonvulsants
Respiratory and Gastrointestinal 161-180 Bronchodilators, Corticosteroids, 10%
Drugs Antiemetics, PPIs
Special Populations and 181-200 Pediatrics, Geriatrics, Pregnancy, Drug 10%
Toxicology Overdose Management
Page 2
,Q1. A drug displays Michaelis-Menten kinetics with a Vmax of 40 mg/h and Km of 5
mg/L. If the patient's hepatic blood flow is reduced by 50% due to heart failure, what
is the most likely effect on the drug's steady-state concentration when administered at
a dose of 60 mg/day?
A. Decrease due to increased free fraction
B. Increase disproportionately to the reduction in clearance
C. No change because capacity-limited clearance is independent of blood flow
D. Decrease because of reduced first-pass metabolism
Correct Answer: B. Increase disproportionately to the reduction in clearance
Rationale: Drugs with capacity-limited (saturable) clearance have a clearance that
depends on intrinsic enzyme activity, not blood flow. However, when the dose approaches
Vmax, a small reduction in clearance causes a large increase in steady-state
concentration, since Cp = (rate of administration) / clearance. Reduced hepatic blood flow
does not directly affect intrinsic clearance, but in this case, the drug's concentration is
already near saturation, so the reduction in clearance (from any cause) leads to a
disproportionate rise. Options A and D are incorrect because blood flow reduction does
not increase free fraction or reduce first-pass metabolism for a low-extraction drug.
Why Wrong:
A - Free fraction is determined by protein binding, not hepatic blood flow.
C - While capacity-limited clearance is independent of blood flow, the concentration
does change if clearance is altered by other factors; here, the question states blood
flow reduction, but the effect is still on total clearance.
D - First-pass metabolism is not the primary determinant for a low-extraction drug.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4:
Pharmacokinetics.
Q2. A patient on warfarin is prescribed metronidazole for a dental infection. Which
of the following best describes the pharmacodynamic/pharmacokinetic interaction
that necessitates a dose adjustment?
A. Metronidazole displaces warfarin from albumin, increasing free warfarin
concentration.
B. Metronidazole inhibits CYP2C9, reducing warfarin metabolism and increasing INR.
C. Metronidazole induces CYP3A4, increasing warfarin clearance and reducing INR.
D. Metronidazole antagonizes vitamin K epoxide reductase, directly enhancing
warfarin's effect.
Correct Answer: B. Metronidazole inhibits CYP2C9, reducing warfarin metabolism
and increasing INR.
Rationale: Metronidazole is a potent inhibitor of CYP2C9, the primary enzyme
responsible for metabolizing the S-enantiomer of warfarin. This inhibition decreases
warfarin clearance, leading to elevated INR and increased bleeding risk. Warfarin is
Page 3
, highly protein-bound, but displacement interactions are clinically negligible because the
increased free fraction is rapidly metabolized. Metronidazole does not induce CYP3A4 or
directly affect vitamin K epoxide reductase.
Why Wrong:
A - Plasma protein displacement is transient and not the primary mechanism for this
clinically significant interaction.
C - Metronidazole is an inhibitor, not an inducer, of CYP enzymes.
D - Warfarin itself inhibits VKOR; metronidazole does not have this direct effect.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 26:
Anticoagulant Drugs.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 25
mL/min/1.73m²) is currently on metformin. According to current guidelines, which of
the following is the most appropriate recommendation?
A. Continue metformin at the same dose; it is safe at any eGFR.
B. Discontinue metformin immediately due to contraindication at eGFR < 30.
C. Reduce metformin dose by 50% and monitor renal function monthly.
D. Switch to metformin extended-release to reduce renal excretion.
Correct Answer: B. Discontinue metformin immediately due to contraindication at
eGFR < 30.
Rationale: Current FDA guidelines state that metformin is contraindicated when eGFR
falls below 30 mL/min/1.73m² due to the risk of lactic acidosis. At eGFR 25, the drug
should be discontinued. While some guidelines allow reduced doses down to eGFR 30,
below that threshold the risk outweighs benefit. Extended-release formulations do not alter
renal clearance.
Why Wrong:
A - Metformin is not safe at any eGFR; it is contraindicated below 30.
C - Dose reduction is recommended for eGFR 30-45, not below 30.
D - Extended-release metformin has the same renal clearance and contraindication.
Reference: ADA Standards of Medical Care in Diabetes, 2024; FDA Metformin Label.
Q4. A patient is prescribed a drug that is a weak acid with a pKa of 4.4. If the urine
pH is 8.0, which of the following statements best describes the drug's renal excretion?
A. The drug will be mostly ionized and reabsorbed, reducing excretion.
B. The drug will be mostly non-ionized and reabsorbed, reducing excretion.
C. The drug will be mostly ionized and trapped in the urine, increasing excretion.
D. The drug will be mostly non-ionized and excreted rapidly in the urine.
Correct Answer: C. The drug will be mostly ionized and trapped in the urine,
increasing excretion.
Page 4
Document | 2026/2027 Edition | 200 Verified Questions
NR 565 Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice test is meticulously designed for nursing students preparing for the NR
565 Advanced Pharmacology midterm. It features 200 verified questions with detailed rationales,
covering essential pharmacological principles, drug classifications, and clinical applications. The
content is aligned with the latest 2026-2027 academic guidelines, ensuring relevance and accuracy.
Each question is crafted to mirror the exam format, providing a realistic simulation to enhance
readiness and confidence.
Key Features:
Pharmacokinetics and pharmacodynamics
Autonomic nervous system drugs
Cardiovascular pharmacology
Antimicrobial therapy
Endocrine and metabolic agents
Pain management and CNS drugs
Updates for 2026:
- Integrated 2026-2027 evidence-based prescribing guidelines
- Revised rationales to reflect current clinical protocols
- Added new questions on emerging drug therapies
- Updated drug interactions and safety alerts
- Enhanced distractors to better assess critical thinking
Abstract:
This practice test is an indispensable resource for advanced pharmacology students, offering a rigorous
assessment of knowledge required for the NR 565 midterm. The 200 questions are distributed across core content
areas, each with detailed rationales that explain correct answers and common misconceptions. The test emphasizes
clinical decision-making, drug safety, and patient-centered care, aligning with the competencies expected of
advanced practice nurses. By engaging with this material, students will solidify their understanding of
pharmacological mechanisms, therapeutic applications, and adverse effects. The rationales are designed to
reinforce learning and promote retention, making this an effective study tool. Updated to reflect the latest
guidelines, this practice test ensures that students are well-prepared for the challenges of the exam and future
clinical practice.
Keywords:
Advanced Pharmacology, NR 565, Midterm Exam, Practice Test, Pharmacokinetics, Drug Interactions, Clinical
Guidelines, Nursing Education
Answer Format:
Each question is followed by four answer choices, with the correct answer clearly indicated. A detailed rationale
explains why the correct answer is right and why the distractors are incorrect, referencing pharmacological
principles and clinical guidelines. This format facilitates deep understanding and application of knowledge.
Compliance Checklist:
Aligned with 2026-2027 AACN and ANA guidelines
Reflects current FDA-approved drug indications
Page 1
, Includes safety alerts and black box warnings
Covers all major drug classes in the NR 565 syllabus
Rationales cite evidence-based sources
Suitable for self-assessment and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-20 Absorption, Distribution, Metabolism, 10%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 21-40 Cholinergic, Anticholinergic, Adrenergic, 10%
Drugs Antiadrenergic Agents
Cardiovascular Pharmacology 41-70 Antihypertensives, Antiarrhythmics, 15%
Antianginals, Heart Failure Drugs
Antimicrobial Therapy 71-100 Antibiotics, Antivirals, Antifungals, 15%
Antiparasitics
Endocrine and Metabolic Agents 101-130 Insulin, Oral Hypoglycemics, Thyroid 15%
Drugs, Corticosteroids
Pain Management and CNS 131-160 Opioids, NSAIDs, Antidepressants, 15%
Drugs Anticonvulsants
Respiratory and Gastrointestinal 161-180 Bronchodilators, Corticosteroids, 10%
Drugs Antiemetics, PPIs
Special Populations and 181-200 Pediatrics, Geriatrics, Pregnancy, Drug 10%
Toxicology Overdose Management
Page 2
,Q1. A drug displays Michaelis-Menten kinetics with a Vmax of 40 mg/h and Km of 5
mg/L. If the patient's hepatic blood flow is reduced by 50% due to heart failure, what
is the most likely effect on the drug's steady-state concentration when administered at
a dose of 60 mg/day?
A. Decrease due to increased free fraction
B. Increase disproportionately to the reduction in clearance
C. No change because capacity-limited clearance is independent of blood flow
D. Decrease because of reduced first-pass metabolism
Correct Answer: B. Increase disproportionately to the reduction in clearance
Rationale: Drugs with capacity-limited (saturable) clearance have a clearance that
depends on intrinsic enzyme activity, not blood flow. However, when the dose approaches
Vmax, a small reduction in clearance causes a large increase in steady-state
concentration, since Cp = (rate of administration) / clearance. Reduced hepatic blood flow
does not directly affect intrinsic clearance, but in this case, the drug's concentration is
already near saturation, so the reduction in clearance (from any cause) leads to a
disproportionate rise. Options A and D are incorrect because blood flow reduction does
not increase free fraction or reduce first-pass metabolism for a low-extraction drug.
Why Wrong:
A - Free fraction is determined by protein binding, not hepatic blood flow.
C - While capacity-limited clearance is independent of blood flow, the concentration
does change if clearance is altered by other factors; here, the question states blood
flow reduction, but the effect is still on total clearance.
D - First-pass metabolism is not the primary determinant for a low-extraction drug.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4:
Pharmacokinetics.
Q2. A patient on warfarin is prescribed metronidazole for a dental infection. Which
of the following best describes the pharmacodynamic/pharmacokinetic interaction
that necessitates a dose adjustment?
A. Metronidazole displaces warfarin from albumin, increasing free warfarin
concentration.
B. Metronidazole inhibits CYP2C9, reducing warfarin metabolism and increasing INR.
C. Metronidazole induces CYP3A4, increasing warfarin clearance and reducing INR.
D. Metronidazole antagonizes vitamin K epoxide reductase, directly enhancing
warfarin's effect.
Correct Answer: B. Metronidazole inhibits CYP2C9, reducing warfarin metabolism
and increasing INR.
Rationale: Metronidazole is a potent inhibitor of CYP2C9, the primary enzyme
responsible for metabolizing the S-enantiomer of warfarin. This inhibition decreases
warfarin clearance, leading to elevated INR and increased bleeding risk. Warfarin is
Page 3
, highly protein-bound, but displacement interactions are clinically negligible because the
increased free fraction is rapidly metabolized. Metronidazole does not induce CYP3A4 or
directly affect vitamin K epoxide reductase.
Why Wrong:
A - Plasma protein displacement is transient and not the primary mechanism for this
clinically significant interaction.
C - Metronidazole is an inhibitor, not an inducer, of CYP enzymes.
D - Warfarin itself inhibits VKOR; metronidazole does not have this direct effect.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 26:
Anticoagulant Drugs.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 25
mL/min/1.73m²) is currently on metformin. According to current guidelines, which of
the following is the most appropriate recommendation?
A. Continue metformin at the same dose; it is safe at any eGFR.
B. Discontinue metformin immediately due to contraindication at eGFR < 30.
C. Reduce metformin dose by 50% and monitor renal function monthly.
D. Switch to metformin extended-release to reduce renal excretion.
Correct Answer: B. Discontinue metformin immediately due to contraindication at
eGFR < 30.
Rationale: Current FDA guidelines state that metformin is contraindicated when eGFR
falls below 30 mL/min/1.73m² due to the risk of lactic acidosis. At eGFR 25, the drug
should be discontinued. While some guidelines allow reduced doses down to eGFR 30,
below that threshold the risk outweighs benefit. Extended-release formulations do not alter
renal clearance.
Why Wrong:
A - Metformin is not safe at any eGFR; it is contraindicated below 30.
C - Dose reduction is recommended for eGFR 30-45, not below 30.
D - Extended-release metformin has the same renal clearance and contraindication.
Reference: ADA Standards of Medical Care in Diabetes, 2024; FDA Metformin Label.
Q4. A patient is prescribed a drug that is a weak acid with a pKa of 4.4. If the urine
pH is 8.0, which of the following statements best describes the drug's renal excretion?
A. The drug will be mostly ionized and reabsorbed, reducing excretion.
B. The drug will be mostly non-ionized and reabsorbed, reducing excretion.
C. The drug will be mostly ionized and trapped in the urine, increasing excretion.
D. The drug will be mostly non-ionized and excreted rapidly in the urine.
Correct Answer: C. The drug will be mostly ionized and trapped in the urine,
increasing excretion.
Page 4
